Literature DB >> 8053145

Effects of the gag region on genome stability: avian retroviral vectors that contain sequences from the Bryan strain of Rous sarcoma virus.

M J Federspiel1, S H Hughes.   

Abstract

We have previously described replication-competent Schmidt Ruppin-A Rous sarcoma virus (RSV)-based retroviral vectors that can be used to deliver and express genes in avian cells. We have continued to modify the prototype vectors to develop a more versatile and efficient system. Substitution of the polymerase (pol) region from the Bryan high-titer RSV (BH-RSV) for the SR-A RSV pol region of these retroviral vectors causes these viruses to replicate more efficiently. We cloned the gag regions from two independent BH-RSV-transformed cell lines and tested whether substituting either of these gag regions would improve the replication and/or gene expression of the vectors. Chimeric vectors were constructed in which the gag region of the prototype vector (SR-A RSV) was replaced with the corresponding segment of BH-RSV gag in vectors that had either the original SR-A RSV pol or the BH-RSV pol region. All vectors contained the bacterial chloramphenicol acetyltransferase gene (CAT). The results indicate that different SR-A RSV and BH-RSV gag-pol chimeras can significantly affect the level of viral and CAT gene expression. The insertion of one of the BH-RSV gag regions, but not the other, gave rise to viruses with unstable genomes.

Entities:  

Mesh:

Year:  1994        PMID: 8053145     DOI: 10.1006/viro.1994.1478

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

1.  An Mpsi-containing heterologous RNA, but not env mRNA, is efficiently packaged into avian retroviral particles.

Authors:  J D Banks; B O Kealoha; M L Linial
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Proviruses selected for high and stable expression of transduced genes accumulate in broadly transcribed genome areas.

Authors:  Jirí Plachy; Jan Kotáb; Petr Divina; Markéta Reinisová; Filip Senigl; Jirí Hejnar
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

Review 3.  Replication-competent retroviral vectors for expressing genes in avian cells in vitro and in vivo.

Authors:  E J Bell; P M Brickell
Journal:  Mol Biotechnol       Date:  1997-06       Impact factor: 2.695

4.  Transformation by v-Src: Ras-MAPK and PI3K-mTOR mediate parallel pathways.

Authors:  E Penuel; G S Martin
Journal:  Mol Biol Cell       Date:  1999-06       Impact factor: 4.138

5.  The packaging phenotype of the SE21Q1b provirus is related to high proviral expression and not trans-acting factors.

Authors:  D J Anderson; J Stone; R Lum; M L Linial
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Soluble forms of the subgroup A avian leukosis virus [ALV(A)] receptor Tva significantly inhibit ALV(A) infection in vitro and in vivo.

Authors:  S L Holmen; D W Salter; W S Payne; J B Dodgson; S H Hughes; M J Federspiel
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Expression of a murine leukemia virus Gag-Escherichia coli RNase HI fusion polyprotein significantly inhibits virus spread.

Authors:  M VanBrocklin; A L Ferris; S H Hughes; M J Federspiel
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

8.  An avian sarcoma/leukosis virus-based gene trap vector for mammalian cells.

Authors:  X H Zheng; S H Hughes
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

9.  Alterations in the MA and NC domains modulate phosphoinositide-dependent plasma membrane localization of the Rous sarcoma virus Gag protein.

Authors:  Shorena Nadaraia-Hoke; Darrin V Bann; Timothy L Lochmann; Nicole Gudleski-O'Regan; Leslie J Parent
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

10.  The core element of a CpG island protects avian sarcoma and leukosis virus-derived vectors from transcriptional silencing.

Authors:  Filip Senigl; Jirí Plachý; Jirí Hejnar
Journal:  J Virol       Date:  2008-06-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.